Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azacitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacitidine SCHEMBL169369 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL17537438 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL706302 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL20143987 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL10024703 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL13390797 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL23815524 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Fazarabine SCHEMBL3278 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL1249475 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL7146234 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20200316099-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | CELGENE CORPORATION | 2020-10-08 | — | — | US | disclosed |
| US-9968627-B2 | Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-9925207-B2 | Methods of treating myelodysplastic syndromes using lenalidomide | CELGENE CORPORATION (US) | 2018-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | DNMT1 403/4885LMNA 1285/4885MTOR 4777/4885 |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | DCTD, CDA, NT5C2 | DNMT1 403/4885LMNA 1285/4885MTOR 4777/4885 |
| US-20200316099-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | UNG, DCTD, DPYD | DNMT1 13/4885LMNA 2638/4885MTOR 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.